Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Staphylococcal Infections: early-phase trial registry
1 of 4 indexed Staphylococcal Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Staphylococcal Infections: 4 US clinical trials tracked, 1 recruiting.
Staphylococcal Infections is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is NovaDigm Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition staphylococcal-infections
OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Staphylococcal Infections lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Staphylococcal Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Staphylococcal Infections is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Modeling Host-Pathogen Interaction Using Lymphoid Organoids
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06479837
Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine
NovaDigm Therapeutics
NCT01447407
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
Destiny Pharma
NCT03915470
Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
Pfizer
NCT02364596
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Staphylococcal Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Staphylococcal Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Staphylococcal Infections page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Staphylococcal Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- NovaDigm Therapeutics sponsors the most Staphylococcal Infections trials on record, review their full trial history before evaluating a specific study. See NovaDigm Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Staphylococcal Infections condition card totals 4 registered trials; most-linked intervention NDV-3 vaccine without alum ID; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.